{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T14:17:39Z","timestamp":1783693059134,"version":"3.55.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Fundaci\u00f3 Instituci\u00f3 dels Centres de Recerca de Catalunya"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ther Innov Regul Sci"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Access to cross-border clinical trials may represent the sole therapeutic option for children living with rare diseases for which no approved medicines exist. Many children are excluded from participation in trials due to language restrictions. There are insufficient comprehensive analyses of the experiences and preferences of parents across Europe concerning participation and exclusion of their child in international clinical trials, particularly regarding language support during enrollment in cross-border clinical research studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>An anonymous online survey was designed and translated into 22 official European languages to collect data from parents of children living with a disease across Europe. The survey included five sections: (1) sociodemographic information; (2) experience participating in a clinical trial; (3) experience in cases where the patient was unable to take part in a study abroad; (4) experience participating in a clinical trial abroad; and (5) preferences regarding decentralized trial options.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>1,436 responses were analyzed from parents across 34 European countries. Key findings: 55.7% of the parents reported being able to communicate in English. 10.7% had prior clinical trial experience, of whom 30.1% traveled abroad to enable their child to participate. Among those reporting being excluded from cross-border trials, 34.7% cited language barriers or country of residence as the reason. Most families expressed a strong willingness to accept decentralized trial options, regardless of where the study may be conducted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Accommodating language translation to permit participation in a clinical trial abroad is feasible. While a significant percentage of caregivers of pediatric patients in Europe could communicate in English, approximately one-third of those excluded from clinical trials cited language barriers or country of residence as the reason. When translation was required, the most commonly offered solution was the use of professional interpreters, an accommodation that could enable broader patient participation in essential research.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s43441-026-00942-y","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T16:54:33Z","timestamp":1773852873000},"page":"1037-1048","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Parents' Perspectives on Access to Pediatric Rare Disease Cross-Border Clinical Trials in Europe: Experiences of Language Inclusion and Preferences"],"prefix":"10.1007","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4494-3663","authenticated-orcid":false,"given":"Begonya","family":"Nafria","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6854-7366","authenticated-orcid":false,"given":"Segolene","family":"Gaillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8219-7809","authenticated-orcid":false,"given":"Martine","family":"Dehlinger-Kremer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1696-0757","authenticated-orcid":false,"given":"Pamela","family":"Dicks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7253-6475","authenticated-orcid":false,"given":"Ricardo M.","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8414-3233","authenticated-orcid":false,"given":"Lucy","family":"Bray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6448-8170","authenticated-orcid":false,"given":"Barbara E.","family":"Bierer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9663-0872","authenticated-orcid":false,"given":"Bob","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,18]]},"reference":[{"key":"942_CR1","unstructured":"Regulation (EU) No\u00a0536\/2014 of the European Parliament and of the Council of 16\u00a0April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001\/20\/EC. Link: https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/HTML\/?uri=CELEX:32014R0536 Accessed: 24th of January 2026"},{"key":"942_CR2","unstructured":"Regulation (EC) No 1901\/2006 of the european parliament and of the council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No 1768\/92, Directive 2001\/20\/EC, Directive 2001\/83\/EC and Regulation (EC) No\u00a0726\/2004. Accessed: 24th of January 2026 https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/HTML\/?uri=CELEX:32006R1901"},{"key":"942_CR3","unstructured":"https:\/\/accelerating-clinical-trials.europa.eu\/index_en Accessed: 24th of January 2026"},{"key":"942_CR4","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2024-086527","volume":"15","author":"GM Abozaid","year":"2025","unstructured":"Abozaid GM, Kerr K, Alomary H, et al. Global insight into rare disease and orphan drug definitions: a systematic literature review. BMJ Open. 2025;15:e086527. https:\/\/doi.org\/10.1136\/bmjopen-2024-086527.","journal-title":"BMJ Open"},{"key":"942_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41390-025-03845-0","author":"AV Muthukumar","year":"2025","unstructured":"Muthukumar AV, Shah KM, Glynn RJ, et al. Persistent exclusion of non-English speakers in pediatric research: a national analysis using ClinicalTrials.gov. 2025. Pediatr Res. https:\/\/doi.org\/10.1038\/s41390-025-03845-0."},{"issue":"1","key":"942_CR6","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1001\/jamapediatrics.2022.3828","volume":"177","author":"A Chen","year":"2023","unstructured":"Chen A, Demaestri S, Schweiberger K, et al. Inclusion of non\u2013english-speaking participants in Pediatric health research: a review. JAMA Pediatr. 2023;177(1):81\u20138. https:\/\/doi.org\/10.1001\/jamapediatrics.2022.3828.","journal-title":"JAMA Pediatr"},{"key":"942_CR7","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.31841","author":"DJ Zheng","year":"2025","unstructured":"Zheng DJ, Rodday AM, Castellino SM, Renfro LA, Lerner D, Henderson TO, et al. Caregiver at-work productivity loss at the time of a child\u2019s diagnosis with high-risk Hodgkin lymphoma: a report from the Children\u2019s Oncology Group AHOD1331 study. Pediatr Blood Cancer. 2025. https:\/\/doi.org\/10.1002\/pbc.31841.","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"942_CR8","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.4715","volume":"8","author":"AP Ganguly","year":"2025","unstructured":"Ganguly AP, Martin R, Barnett E, et al. Childcare barriers and appointment nonadherence among women in a safety-net health system. JAMA Netw Open. 2025;8(4):e254715. https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.4715.","journal-title":"JAMA Netw Open"},{"key":"942_CR9","unstructured":"http:\/\/enprema.ema.europa.eu\/enprema Accessed: 24th of January 2026"},{"key":"942_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-022-01026-w","volume":"14","author":"S Marwaha","year":"2022","unstructured":"Marwaha S, Knowles JW, Ashley EA. A guide for the diagnosis of rare and undiagnosed disease: beyond the exome. Genome Med. 2022;14:23. https:\/\/doi.org\/10.1186\/s13073-022-01026-w.","journal-title":"Genome Med"},{"key":"942_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.585722","volume":"7","author":"T Lalova","year":"2020","unstructured":"Lalova T, Padeanu C, Negrouk A, Lacombe D, Geissler J, Klingmann I, et al. Cross-border access to clinical trials in the EU: exploratory study on needs and reality. Front Med. 2020;7:585722. https:\/\/doi.org\/10.3389\/fmed.2020.585722.","journal-title":"Front Med"},{"key":"942_CR12","unstructured":"Assessing the clinical trial ecosystem in Europe. IQVIA. Date of publication: October, 2024. https:\/\/www.efpia.eu\/media\/o2gjnmfu\/efpia_ve_iqvia_assessing-the-clinical-trial-ct-ecosystem.pdf Accessed: 24th of January 2026"},{"key":"942_CR13","unstructured":"Key performance indicators (KPIs) to monitor the European clinical trials environment. Metrics on the Clinical Trials Regulation and Clinical Trials Directive. 30 June 2023, edition 15. ACT EU_KPIs to monitor the European clinical trials environment_edition 15 Accessed: 24th of January 2026"},{"issue":"6","key":"942_CR14","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1038\/sj.bjc.6602423","volume":"92","author":"Z Nurgat","year":"2005","unstructured":"Nurgat Z, Craig W, Campbell N, et al. Patient motivations surrounding participation in phase I and phase II clinical trials of cancer chemotherapy. Br J Cancer. 2005;92(6):1001\u20135. https:\/\/doi.org\/10.1038\/sj.bjc.6602423.","journal-title":"Br J Cancer"},{"key":"942_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-015-1105-3","volume":"17","author":"SY Moorcraft","year":"2016","unstructured":"Moorcraft SY, Marriott C, Peckitt C, et al. Patients\u2019 willingness to participate in clinical trials and their views on aspects of cancer research: results of a prospective patient survey. Trials. 2016;17:17. https:\/\/doi.org\/10.1186\/s13063-015-1105-3.","journal-title":"Trials"},{"key":"942_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/bmjmed-2024-000984","volume":"3","author":"D Collister","year":"2024","unstructured":"Collister D, Song C, Ruzycki SM. Fostering diversity in clinical trials: need for evidence and implementation to improve representation. BMJ Med. 2024;3:e000984. https:\/\/doi.org\/10.1136\/bmjmed-2024-000984.","journal-title":"BMJ Med"},{"key":"942_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2022.106740","volume":"116","author":"MD Kelsey","year":"2022","unstructured":"Kelsey MD, Patrick-Lake B, Abdulai R, Broedl UC, Brown A, Cohn E, et al. Inclusion and diversity in clinical trials: actionable steps to drive lasting change. Contemp Clin Trials. 2022;116:106740. https:\/\/doi.org\/10.1016\/j.cct.2022.106740.","journal-title":"Contemp Clin Trials"},{"issue":"6","key":"942_CR18","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1056\/NEJMp2215609","volume":"388","author":"AL Schwartz","year":"2023","unstructured":"Schwartz AL, Alsan M, Morris AA, Halpern SD. Why diverse clinical trial participation matters. N Engl J Med. 2023;388(6):1252\u20134. https:\/\/doi.org\/10.1056\/NEJMp2215609.","journal-title":"N Engl J Med"},{"key":"942_CR19","unstructured":"World report on social determinants of health equity. World Health Organization. 2025. https:\/\/www.who.int\/publications\/i\/item\/9789240107588 Accessed: 24th of January 2026"},{"key":"942_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s12992-015-0091-2","volume":"11","author":"JM Spiegel","year":"2015","unstructured":"Spiegel JM, Breilh J, Yassi A. Why language matters: insights and challenges in applying a social\u00a0determination\u00a0of health approach in a North-South collaborative research program. Glob Health. 2015;11:9. https:\/\/doi.org\/10.1186\/s12992-015-0091-2.","journal-title":"Glob Health"},{"key":"942_CR21","unstructured":"United Nations. Universal Declaration of Human Rights. United Nations General Assembly Resolution 217 A (III). 1948. Retrieved from https:\/\/www.un.org\/en\/about-us\/universal-declaration-of-human-rights Accessed: 24th of January 2026"},{"key":"942_CR22","unstructured":"Charter of Fundamental Rights of the European Union (18.12.2000) Official Journal of the European Communities. C364\/9 https:\/\/www.europarl.europa.eu\/charter\/pdf\/text_en.pdf Accessed: 24th of January 2026"},{"key":"942_CR23","unstructured":"Convention on the Rights of the Child, Nov. 20, 1989. https:\/\/www.unicef.org.uk\/wp-content\/uploads\/2016\/08\/unicef-convention-rights-child-uncrc.pdf Accessed: 24th of January 2026"},{"key":"942_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2019.105812","volume":"84","author":"B Luke Gelinas","year":"2019","unstructured":"Luke Gelinas B, Crawford A, Kelman BE, Bierer R. Relocation of study participants for rare and ultra-rare disease trials: ethics and operations. Contemp Clin Trials. 2019;84:105812. https:\/\/doi.org\/10.1016\/j.cct.2019.105812.","journal-title":"Contemp Clin Trials"},{"key":"942_CR25","doi-asserted-by":"publisher","DOI":"10.1002\/nop2.70048","volume":"11","author":"L N.\u00a0Bulto","year":"2024","unstructured":"N.\u00a0Bulto L. Voices unheard: bridging language gaps, ensuring equity and inclusion of non-native speakers in health research and clinical trials. Nurs Open. 2024;11:e70048. https:\/\/doi.org\/10.1002\/nop2.70048.","journal-title":"Nurs Open"},{"key":"942_CR26","unstructured":"Resolution on \u201cRare diseases: a global health priority for equity and inclusion\u201d. World Health Organization. https:\/\/apps.who.int\/gb\/ebwha\/pdf_files\/WHA78\/A78_R11-en.pdf Accessed: 24th of January 2026"},{"key":"942_CR27","unstructured":"Guidance for best practices for clinical trials. Geneva: World Health Organization; 2024. Licence: CC\u00a0BY-NC-SA\u00a03.0\u00a0IGO https:\/\/iris.who.int\/bitstream\/handle\/10665\/378782\/9789240097711-eng.pdf Accessed on the 24th of January 2026"}],"container-title":["Therapeutic Innovation &amp; Regulatory Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43441-026-00942-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43441-026-00942-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43441-026-00942-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T13:49:53Z","timestamp":1783691393000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43441-026-00942-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,18]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["942"],"URL":"https:\/\/doi.org\/10.1007\/s43441-026-00942-y","relation":{"references":[{"id-type":"doi","id":"10.1038\/s41390-025-03845-0","asserted-by":"subject"}],"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7899082\/v1","asserted-by":"object"}]},"ISSN":["2168-4790","2168-4804"],"issn-type":[{"value":"2168-4790","type":"print"},{"value":"2168-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,18]]},"assertion":[{"value":"19 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}